| Prev Close | 62.82 |
| Open | 62.24 |
| Day Low/High | 61.92 / 62.41 |
| 52 Wk Low/High | 47.83 / 64.60 |
| Volume | 5.05M |
| Avg Volume | 5.59M |
| Exchange | NYSE |
| Shares Outstanding | 1.75B |
| Market Cap | 110.29B |
| EPS | 0.30 |
| P/E Ratio | 299.57 |
| Div & Yield | 1.12 (1.73%) |
Markets bathed in the afterglow of the strong jobs report for most of the week.
ABBOTT PARK, Ill., June 8, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share.
Looking for good stock ideas? TheStreet has you covered with a plethora of names gleaned from our readings.
Markets go through a short and volatile week.
STATE-OF-THE-ART MULTI-ASSAY TEST SYSTEM HELPS PEOPLE WITH DIABETES GET THE HbA1c RESULTS THEY NEED WITHIN 3 MINUTES -- ALLOWING MORE TIME FOR CONSULTATION AND CARE DURING A SINGLE HEALTHCARE VISIT
The Memorial Day holiday is now over, and it's time for investors to get back to work looking for top stocks. TheStreet's founder Jim Cramer has a must watch list.
When chartists look for the next market leaders they often go to stocks that have held up the best during corrections.
When rates decline, most of the S&P 500 benefits, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
The crash of oil will only accelerate the move.
China trade wars, North Korea tensions and oil volatility hit the markets this week.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Abbott Laboratories has taken over the #38 spot from NextEra Energy Inc , according to ETF Channel. Below is a chart of Abbott Laboratories versus NextEra Energy Inc plotting their respective rank within the S&P 500 over time (ABT plotted in blue; NEE plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
- XIENCE Sierra™, the newest generation of XIENCE drug-eluting stents, received U.S. Food and Drug Administration (FDA) approval
- Promising results for Tendyne valve presented as late-breaking clinical trial at EuroPCR
Conference highlights from Honeywell bolster the investment case.
- Late-breaking data presented at EuroPCR and simultaneously published in "The New England Journal of Medicine" support use of Abbott's PressureWire™ guidewire to help physicians make stenting decisions
Markets consolidate after recent gains
Jim discusses Macy's quarter as a readthrough to Nordstrom, defense and North Korea, and more on the market!
President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.
The markets strongly rebounded this week as a few of the major averages pushed into positive year-to-date territory.
A strong Friday failed to keep markets in positive territory.
- ADVISOR™ HD GRID MAPPING CATHETER, SENSOR ENABLED™ FACILITATES IMPROVED DATA COLLECTION, SUPPORTING OPTIMAL TREATMENT FOR PATIENTS WITH COMPLEX CARDIAC ARRHYTHMIAS
- Provides patients with access to latest-generation gold-standard heart stent through Japan's health insurance system
Markets end flat for week as strong earnings fail to excite investors.
On a rough day for markets we review new additions to our investing bullpen.
LONG-TERM AGREEMENT BETWEEN SANQUIN, A LEADER IN BLOOD SERVICES, AND ABBOTT, A GLOBAL LEADER IN TRANSFUSION MEDICINE, HELPS ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY IN THE NETHERLANDS
Markets give up some gains Thursday and Friday, ahead of heavy earnings next week.
Stocks finish mixed on Wednesday amid a sharp decline in IBM shares.
